Archive
Sustainability Report 2023
As a Benefit Corporation, Chiesi Farmaceutici carefully assesses its environmental and societal sustainability performance every year. Measuring and evaluating each operation is a fundamental aspect of the company commitment to transparency and accountability towards its stakeholders.
Progress in the crucial areas of work is regularly assessed, clearly identifying areas for improvement for Chiesi’s core areas: Patients, Planet, People and Prosperity.
The Sustainability Report provides a complete and precise summary of how Chiesi promotes sustainable care, together with patients, partners, suppliers and healthcare professionals who are an integral part of its system.
ESG Report 2023
In the reporting of sustainability data, Chiesi Group takes a multidimensional approach considering both regulatory frameworks and voluntary reporting frameworks in order to create an overall overview that is as complete and transparent as possible.
Climate Transition Plan
The Group has adopted a robust Climate Transition Plan ahead of the anticipated regulatory requirements of the Corporate Sustainability Reporting Directive (CSRD). This document serves as a strategic roadmap to meet emission reduction targets and ensures long-term resilience and adaptability in addressing climate-related challenges.
Chiesi at a Glance
By clicking the button on the side, you can access "Chiesi at a Glance", a snapshot of the Chiesi Group's key achievements in 2023. This document, together with the Sustainability Report, completes the company's annual reporting.
Annual & Sustainability Report 2022
Since becoming a Benefit Corporation and certified B Corp, Chiesi diligently evaluates its sustainability performance on an annual basis.
Measuring and evaluating our operations is a fundamental aspect of our corporate pledge to transparency and accountability towards society. We continually gauge progress in our crucial areas of work, while openly identifying areas for improvement.
The Sustainability Report provides a comprehensive and timely account of how we drive sustainable care together – with our patients, our partners, our suppliers, and all healthcare professionals that are part of our system.
Chiesi at Glance
Please click on the download button to read the “Chiesi at a Glance” , a snapshot of Chiesi Group’s main milestones achieved in 2022 which, together with the Sustainability Report, completes the company’s annual reporting.
Annual & Sustainability Report 2021
As a Benefit Corporation and a B Corp certified company, sustainability is an essential part of our business. This is why we have decided, starting in 2019, to include in one single publication financial, social and environmental data.
The Annual & Sustainability Report 2021 provides an accurate description of the Group’s activities at Headquarters and Affiliates level. This year, Chiesi colleagues around the world were also invited to tell a story related to their work and the Covid-19 pandemic, the #EveryStoryCounts narrative. Click on the image on the left and discover the Annual & Sustainability Report 2021.
Annual & Sustainability Report 2020
As a Benefit Corporation and a B Corp certified company, sustainability is an essential part of our business. This is why we have decided, starting in 2019, to include in one single publication financial, social and environmental data.
The Annual & Sustainability Report 2020 provides an accurate description of the Group’s activities at Headquarters and Affiliates level. This year, Chiesi colleagues around the world were also invited to tell a story related to their work and the Covid-19 pandemic, the #EveryStoryCounts narrative. Click on the image on the left and discover the Annual & Sustainability Report 2020.
Annual & Sustainability Report 2019
As a Benefit Corporation and a B Corp certified company, sustainability is an essential part of our business. This is why we have decided, starting in 2019, to include in one single publication financial, social and environmental data.
The Annual & Sustainability Report 2019 provides an accurate description of the Group’s activities at Headquarters and Affiliates level. This year, Chiesi colleagues around the world were also invited to tell a story related to their work and the Covid-19 pandemic, the #EveryStoryCounts narrative. Click on the image on the left and discover the Annual & Sustainability Report 2019.
Corporate Social Responsibility Report
The Chiesi Corporate Social Responsibility framework is based on three pillars: PEOPLE, ETHICS & COMPLIANCE and ENVIRONMENT & SAFETY.
Annual Report 2014
In 2014, initiatives aimed at strengthening the Chiesi Group continued, both with regard to the capacity for sustainable growth and to the enhancement of Research and Development and internationalisation activities.
Annual Report 2013
Biomedical research today speaks with an American accent. This is only a recent phenomenon and through concerted efforts in Europe and elsewhere US dominance in life sciences innovation is being challenged.
Annual Report 2012
2012 was a year characterised by the complete overhaul of the company’s organisational model, with the aim of placing the Group in the ideal conditions to ensure there is the right level of focus on growth.
Annual Report 2011
Biomedical research today speaks with an American accent. This is only a recent phenomenon and through concerted efforts in Europe and elsewhere US dominance in life sciences innovation is being challenged.
Annual Report 2010
The Chiesi Group’s consolidated sales stood at 1.015 million Euro, and were up by 16.4% on the previous year.
Annual Report 2009
Including consolidation of Cornerstone turnover starting in the August 2009, total sales reached € 872 million, increasing by 16.5% over the previous year. Excluding data for the new American affiliate, sales reached € 842 million, which is an increase of 13.1%...
Annual Report 2008
Consolidated sales have reached 748.8 million, and are up by 14.1% on the previous year, a growth rate far higher than that seen in the European market.
Annual Report 2007
Consolidated sales reached Euro 656 million, an increase of 10.6% on the previous year, indicating a growth rate significantly higher than that recorded on the European market.